Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
Elias Jabbour, Nicholas J. Short, Jayastu Senapati, Nitin Jain, Xuelin Huang, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, William G. Wierda, Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo, Koji Sasaki, Tapan M. Kadia, Joseph D. Khoury, Sa A. Wang, Fadi Haddad, Jovitta Jacob, Rebecca Garris, Farhad Ravandi, Hagop M. Kantarjian
Topics & Concepts
BlinatumomabMedicineAcute lymphocytic leukemiaInternal medicineVincristinePrednisoneAdverse effectGastroenterologyChemotherapyPediatricsLeukemiaCyclophosphamideLymphoblastic LeukemiaChronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia researchCAR-T cell therapy research